Ying Yuan, Ph.D.
Affiliations: | 2005 | University of Michigan, Ann Arbor, Ann Arbor, MI |
Area:
Biostatistics BiologyGoogle:
"Ying Yuan"Parents
Sign in to add mentorRoderick Joseph Alexander Little | grad student | 2005 | University of Michigan | |
(Model-based estimates of the finite population mean for two -stage cluster samples with nonresponse.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Chi X, Yuan Y, Yu Z, et al. (2024) A generalized calibrated Bayesian hierarchical modeling approach to basket trials with multiple endpoints. Biometrical Journal. Biometrische Zeitschrift. 66: e2300122 |
Yuan Y, Zhou H, Liu S. (2024) Statistical and practical considerations in planning and conduct of dose-optimization trials. Clinical Trials (London, England). 17407745231207085 |
Zhao Y, Yuan Y, Korn EL, et al. (2023) Backfilling Patients in Phase I Dose Escalation Trials Using Bayesian Optimal Interval Design (BOIN). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
Zhang W, Laird G, Chen J, et al. (2023) A Bayesian phase II proof-of-concept design for clinical trials with longitudinal endpoints. Statistics in Medicine |
Thall PF, Zang Y, Chapple AG, et al. (2023) Novel clinical trial designs with dose optimization to improve long-term outcomes. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
Lin R, Shi H, Yin G, et al. (2022) BAYESIAN HIERARCHICAL RANDOM-EFFECTS META-ANALYSIS AND DESIGN OF PHASE I CLINICAL TRIALS. The Annals of Applied Statistics. 16: 2481-2504 |
Zhou Y, Lin R, Lee JJ, et al. (2022) TITE-BOIN12: A Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy. Statistics in Medicine |
Lin R, Thall PF, Yuan Y. (2021) A Phase I-II Basket Trial Design to Optimize Dose-Schedule Regimes Based on Delayed Outcomes. Bayesian Analysis. 16: 179-202 |
Jiang L, Li R, Yan F, et al. (2021) Shotgun: A Bayesian seamless phase I-II design to accelerate the development of targeted therapies and immunotherapy. Contemporary Clinical Trials. 106338 |
Shi H, Cao J, Yuan Y, et al. (2021) uTPI: A utility-based toxicity probability interval design for phase I/II dose-finding trials. Statistics in Medicine |